Chinese Academy of Medical Sciences: Carcinoma, Squamous Cell trials

The registry lists 11 Carcinoma, Squamous Cell studies with Chinese Academy of Medical Sciences as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 8Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT04861467Phase 2
• AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCCStatus unknownNCT05522894Phase 2
• Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 ResectionStatus unknownNCT05460403
• The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCsStatus unknownNCT05202275Phase 2
• Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell CarcinomaStatus unknownNCT04851132Not applicable
• Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04390958Phase 2
• Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal CarcinomaStatus unknownNCT04275986Phase 2
• SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell CancerStatus unknownNCT03603756Phase 2
• Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT02461043Phase 3
• Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell CarcinomaCompletedNCT02446574Phase 1/2
• Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung CancerStatus unknownNCT01969955Phase 2